As an iPhone user, you might be unintentionally limiting your device’s potential. Small habits, often overlooked, can impact your phone’s efficiency, usability, and security. By identifying and ...

Apple’s Q1 FY26 earnings report featured a lot of statistics about the company’s products and services, including a new major milestone that encompasses their entire business. Apple now has more than ...

Sullivan is professor of health economics and policy and former dean of pharmacy at the University of Washington. Hansen is professor of health economics and policy and chair of the Department of ...

Amgen Inc. (AMGN) reported strong Q4 2025 results and provided full-year 2026 guidance that was above Street expectations. The company is managing losses of exclusivity on several large products quite ...

Experts say it’ll help a narrow group of people, citing “no clear advantage for most people” to use the platform The Trump administration announced that its discount drug platform, TrumpRx, will ...

Biometric locks like face recognition are convenient to set up—but because of a legal loophole, law enforcement can bypass them more easily than a traditional passcode. I review privacy tools like ...

The new website promises “low cost prescription drugs,” but will not prescribe or sell drugs directly to the patient Dimitrios Kambouris/Getty The Trump administration has announced that its discount ...

Americans will soon be able buy some prescription drugs at discounted cash prices through TrumpRx, a new self-pay website launching Thursday as part of President Donald Trump’s broader push to lower ...

The Trump administration launched a new website, TrumpRx, to offer Americans discounts on prescription drugs. The program aims to lower drug costs through "most-favored-nation-pricing" deals with ...

Are you the type to leave devices plugged in when you leave the house? It's time to reconsider some of them. Corin Cesaric is a Flex Editor at CNET. She received her bachelor's degree in journalism ...

Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug Repatha (evolocumab). In August 2025, the US Food and Drug ...